DD144864A5 - Verfahren zur herstellung von mitteln mit tumorhemmender wirkung - Google Patents

Verfahren zur herstellung von mitteln mit tumorhemmender wirkung Download PDF

Info

Publication number
DD144864A5
DD144864A5 DD79214469A DD21446979A DD144864A5 DD 144864 A5 DD144864 A5 DD 144864A5 DD 79214469 A DD79214469 A DD 79214469A DD 21446979 A DD21446979 A DD 21446979A DD 144864 A5 DD144864 A5 DD 144864A5
Authority
DD
German Democratic Republic
Prior art keywords
sarcosine
tumor
series
endoxan
dose
Prior art date
Application number
DD79214469A
Other languages
German (de)
English (en)
Inventor
Hans Osswald
Mahmoud Youssef
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of DD144864A5 publication Critical patent/DD144864A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Toys (AREA)
  • Window Of Vehicle (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DD79214469A 1978-07-20 1979-07-19 Verfahren zur herstellung von mitteln mit tumorhemmender wirkung DD144864A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782832009 DE2832009A1 (de) 1978-07-20 1978-07-20 Verwendung von sarkosin und sarkosinderivaten ls tumorhemmende wirksubstanzen

Publications (1)

Publication Number Publication Date
DD144864A5 true DD144864A5 (de) 1980-11-12

Family

ID=6044955

Family Applications (1)

Application Number Title Priority Date Filing Date
DD79214469A DD144864A5 (de) 1978-07-20 1979-07-19 Verfahren zur herstellung von mitteln mit tumorhemmender wirkung

Country Status (13)

Country Link
US (1) US4766149A (xx)
EP (1) EP0007597B1 (xx)
JP (1) JPS5519270A (xx)
AT (1) ATE11220T1 (xx)
AU (1) AU529657B2 (xx)
CA (1) CA1151065A (xx)
DD (1) DD144864A5 (xx)
DE (1) DE2832009A1 (xx)
DK (1) DK305479A (xx)
FI (1) FI792218A (xx)
MC (1) MC1271A1 (xx)
NO (1) NO792398L (xx)
ZA (1) ZA793603B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3010599A1 (de) 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
DE3440090A1 (de) * 1984-11-02 1986-05-07 Novo-Med AG, Appenzell Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung
US4916217A (en) * 1987-01-08 1990-04-10 Bristol-Myers Company Phosphorus containing derivatives of epipodophyllotoxin
US4994492A (en) * 1989-01-09 1991-02-19 Foodscience Corporation Treatment of melanoma using N,N-dimethylglycine
US5676978A (en) * 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DE4026184A1 (de) * 1990-08-18 1992-02-20 Henkel Kgaa Verfahren zur verminderung des restgehaltes an freiem alkylierungsmittel in waessrigen loesungen kationischer tenside
AU2003247225A1 (en) * 2002-06-19 2004-01-06 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
US8697679B2 (en) * 2003-03-07 2014-04-15 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
EP1847274A1 (en) * 2006-04-21 2007-10-24 CIPROSA LLC - Corporate Creations Network, Inc. Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy
EP3415910A1 (en) 2017-06-16 2018-12-19 Prevention Medicals s.r.o. A method of quantitative determination of sarcosine in a biological sample using anti-arcosine antibodies and peroxidase-active gold nanoparticles or quantum dots

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE553424C (de) * 1928-04-18 1932-06-27 Karl Luedecke Dr Verfahren zur Herstellung von Praeparaten, die das Wachstum von Geweben durch Verminderung der Teilungsfaehigkeit oder Aufloesung der wuchernden Zellen einschraenken
BE647556A (xx) * 1964-05-06 1964-08-31
FR2085637A1 (fr) * 1970-04-15 1971-12-31 Etude Des Catalyseurs Soc D Composition pharmaceutique utilisable notamment contre l'asthenie
DE2211019C3 (de) * 1972-03-08 1980-08-28 Bayer Ag, 5090 Leverkusen Geschmacksverbessernde Formulierungen oraler Penicilline

Also Published As

Publication number Publication date
NO792398L (no) 1980-01-22
EP0007597A1 (de) 1980-02-06
DK305479A (da) 1980-01-21
US4766149A (en) 1988-08-23
DE2832009C2 (xx) 1988-07-28
ATE11220T1 (de) 1985-02-15
CA1151065A (en) 1983-08-02
AU529657B2 (en) 1983-06-16
MC1271A1 (fr) 1980-05-23
AU4907679A (en) 1980-01-24
JPS5519270A (en) 1980-02-09
EP0007597B1 (de) 1985-01-16
FI792218A (fi) 1980-01-21
DE2832009A1 (de) 1980-01-31
ZA793603B (en) 1980-07-30

Similar Documents

Publication Publication Date Title
DE69317494T2 (de) Zusammensetzungen, die mono oder polyhydroxylierte Aminosäuren zur Behandlung des Insulinunabhängigen Diabetes Mellitus enthalten
DE3031732C2 (xx)
DE3305755C2 (xx)
EP0240829A2 (de) Cancerostatisches Mittel
DE60006810T2 (de) Dicarboxylato-diamin-platin-derivate und zusammensetzungen die diese als antitumormittel enthalten
DE3037770C2 (de) N-Niedrigalkyl-3-phenoxy-1-azetidincarboxamide und diese Verbindungen enthaltende Zubereitungen
DD144864A5 (de) Verfahren zur herstellung von mitteln mit tumorhemmender wirkung
DE3152071C2 (de) Taurinderivate, deren Herstellung und Verwendung in Arzneimitteln
DE3115080A1 (de) Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung
DE2725246C2 (xx)
DE2709506A1 (de) Arzneimittel, enthaltend 10-deazaminopterin
EP0083439A2 (de) 4-Sulfido-oxazaphosphorine und deren Verwendung bei der Krebsbekämpfung und zur Immunsuppression
DE2820794C2 (de) Salze der (-Hcis)-l^-Epoxypropylphosphonsäure, Verfahren zu ihrer Herstellung und diese enthaltendes pharmazeutisches Präparat
DE3153623C2 (xx)
DE1910283C3 (de) Gegen bestimmte Krebsformen wirksames Arzneimittel
DE2749520A1 (de) Harnstoffderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische und veterinaermedizinische zusammensetzungen
DE2953309C2 (de) Cytostatisch wirkende Arzneimittel beziehungsweise pharmazeutische Zubereitungen
DE2748015A1 (de) Arzneimittel zur heilung von boesartigen neubildungen
DE2257360C2 (de) 1-(2-Chloräthyl)-1-nitroso-3-[(2-methyl-4-amino-pyrimidin-5-yl)methyl]harnstoff und Verfahren zu seiner Herstellung
EP0461218B1 (de) Zubereitung eines salzes von oxypurinol in oraler form zur behandlung von hyperuricämie
DE2739659C3 (de) N-2,6-Dichlorphenyl-2-aminopyrimidin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE2314387C3 (de) Arzneimittel zur Behandlung bösartiger Neubildungen
DE3030314A1 (de) Arzneimittel auf sulfonamidbasis
DE2457524A1 (de) Arzneimittel zur beeinflussung des zinkspiegels im mechanismus des zellstoffwechsels
AT300810B (de) Verfahren zur Herstellung neuer Pyridoxinderivate